Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Targeted Treatment
100%
Neurobiology
100%
GABAergic Neurons
100%
Fragile X Mental Retardation 1 (FMR1)
100%
Fragile X Syndrome
100%
Fragile X-related Disorders
100%
Allopregnanolone
37%
Ganaxolone
37%
Clinical Trials
25%
Treatment Trials
25%
GABA Agonist
25%
Fragile X-associated Tremor/ataxia Syndrome (FXTAS)
25%
Intellectual Disability
12%
Clinical Trial Design
12%
Phase I Trial
12%
Inpatient Treatment
12%
Phase II Trial
12%
Genetic Disease
12%
Medical Problems
12%
Autism
12%
Lessons Learned
12%
Metabotropic Glutamate Receptor 5 (mGluR5)
12%
Psychiatric Problems
12%
New Trial
12%
New Wave
12%
Premutation
12%
Neurobehavioral Problems
12%
Riluzole
12%
Tiagabine
12%
Vigabatrin
12%
Targeting Mechanism
12%
Monogenetic
12%
GABA System
12%
Gaboxadol
12%
Gray Zone Alleles
12%
Fragile X-associated Primary Ovarian Insufficiency (FXPOI)
12%
Neuroscience
Neuroscience
100%
Spectrum Disorder
100%
Fragile X Syndrome
100%
Allopregnanolone
37%
Ganaxolone
37%
GABA Agonist
25%
Fragile X-Associated Tremor/Ataxia Syndrome
25%
Atrial Septal Defect
25%
Heart Atrium Septum Defect
25%
Gamma-Aminobutyric Acid
12%
Riluzole
12%
Tiagabine
12%
Vigabatrin
12%
Gaboxadol
12%
Intellectual Disability
12%
Autism
12%
Genetics
12%